MPL and systemic lupus erythematosus: According to Lei and colleagues, c-SLE patients intolerant of rituximab who used another B cell-depleting agent, ofatumumab, also obtained a therapeutic effect.[15] Additional treatments, such as plasmapheresis and thrombopoietin receptor agonists, can be efficacious in patients with refractory TP and active bleeding.